HUTCHMED Reports Orpathys Plus Tagrisso Reduced Progression or Death Risk in Phase III Study
HUTCHMED reported a reduced risk of disease progression or death with Orpathys plus Tagrisso in a Phase III study.
HUTCHMED reported a reduced risk of disease progression or death with Orpathys plus Tagrisso in a Phase III study.